Disclosed is a pharmaceutical composition comprising the following two types of cells: an NK cell and a lymphocyte, or the following three types of cells: an NKT cell, an NK cell and a lymphocyte, all of which are contained in the pharmaceutical composition in the proliferated and activated state. Also disclosed is a method for producing the pharmaceutical composition. The following two types of cells: an NK cell and a lymphocyte, or the following three types of cells: an NKT cell, an NK cell and a lymphocyte can be proliferated and activated almost simultaneously, readily and efficiently, by charging a peripheral blood lymphocyte mixture isolated from a peripheral blood and a lymphocyte culture medium containing interleukin-2 into a culture vessel having both of an anti-human CD3 monoclonal antibody and an anti-human CD161 monoclonal antibody immobilized thereon, and culturing the mixed solution in the culture vessel.NK 세포 및 임파구의 2종류의 세포, 또는, NKT 세포, NK 세포 및 임파구의 3종류의 세포가 증식 및 활성화한 의약 조성물 및 이들의 의약 조성물의 제조방법을 제공한다. 항사람 CD3 모노클로날 항체와 항사람 CD161 모노클로날 항체가 고상화된 배양 용기내에, 말초혈로부터 분리한 말초혈 임파구 혼합물을, 인터로이킨-2를 함유하는 임파구 배양액과 함께 수용하여 배양하는 것에 의해, NK 세포 및 임파구의 2종류의 세포, 또는, NKT 세포, NK 세포 및 임파구의 3종류의 세포를 거의 동시에, 용이하게, 게다가 효율적으로 증식 및 활성화한다.
